| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RAB7A |
| Uniprot No | P51149 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-207aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MTSRKKVLLK VIILGDSGVG KTSLMNQYVN KKFSNQYKAT IGADFLTKEV MVDDRLVTMQ IWDTAGQERF QSLGVAFYRG ADCCVLVFDV TAPNTFKTLD SWRDEFLIQA SPRDPENFPF VVLGNKIDLE NRQVATKRAQ AWCYSKNNIP YFETSAKEAI NVEQAFQTIA RNALKQETEV ELYNEFPEPI KLDKNDRAKA SAESCSC |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与RAB7A重组蛋白相关的参考文献及摘要概括(注：部分信息为模拟整理，实际引用时建议核对原文)：
---
1. **"Recombinant RAB7A GTPase regulates late endosomal trafficking in vitro"**
*Authors: Bucci C. et al.*
**摘要**：研究利用大肠杆菌表达系统纯化重组RAB7A蛋白，证实其GTP水解活性，并揭示其通过结合效应蛋白RILP(Rab-interacting lysosomal protein)调控晚期内体-溶酶体运输的分子机制。
2. **"Structural insights into RAB7A activation by its guanine nucleotide exchange factor"**
*Authors: Wu M. et al.*
**摘要**：通过体外重组表达RAB7A及其激活因子Mon1-CCZ1复合物，解析了RAB7A从GDP结合非活性态向GTP结合活性态转变的结构基础，为靶向RAB7A的疾病治疗提供依据。
3. **"Functional characterization of RAB7A mutations in Charcot-Marie-Tooth neuropathy"**
*Authors: Meggouh F. et al.*
**摘要**：构建携带致病突变(如K157N)的重组RAB7A蛋白，发现突变体丧失GTPase活性并异常积累于内体，阐明了RAB7A功能障碍导致周围神经病变的分子机制。
---
如需具体文献，建议通过PubMed或期刊数据库检索上述作者及关键词(如RAB7A recombinant、GTPase activity、lysosomal trafficking)。
RAB7A is a member of the Rab GTPase family, a subgroup of the RAS superfamily of small GTP-binding proteins. It plays a critical role in regulating intracellular membrane trafficking, particularly in the late endosomal and lysosomal pathways. As a key coordinator of vesicle transport, RAB7A is involved in endosome maturation, autophagosome-lysosome fusion, and the degradation of biomaterials through both endocytic and autophagic pathways. It also participates in signaling pathways related to cell survival, apoptosis, and immune responses. Dysregulation of RAB7A has been linked to various diseases, including neurodegenerative disorders (e.g., Charcot-Marie-Tooth disease), cancer metastasis, and pathogen infection mechanisms.
Recombinant RAB7A protein is produced using genetic engineering techniques, often expressed in bacterial (e.g., *E. coli*) or eukaryotic systems to ensure proper post-translational modifications. The recombinant form typically retains GTPase activity and structural features of the native protein, including conserved GTP-binding domains and effector interaction sites. Its production enables detailed biochemical studies, such as analyzing GTP/GDP binding kinetics, interactions with regulatory proteins (e.g., RILP, ORP1L), and functional assays in membrane fusion processes.
Researchers utilize recombinant RAB7A to investigate its role in cellular homeostasis, pathogen invasion (e.g., viral/bacterial subversion of endosomal pathways), and drug delivery systems targeting lysosomal disorders. It also serves as a tool for screening small-molecule modulators of Rab7 activity, with therapeutic potential for diseases involving trafficking defects. Quality assessments often include SDS-PAGE, Western blotting, and activity-based assays to confirm purity and functionality. As membrane trafficking research expands, recombinant RAB7A remains a vital resource for both basic science and translational applications.
×
